Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH -wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial - GlioME: Gliomagenesis and MicroEnvironment Accéder directement au contenu
Article Dans Une Revue Clinical Cancer Research Année : 2022

Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH -wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial

Louis Garnier
Chrystelle Vidal
  • Fonction : Auteur
Elisabeth Cohen-Jonathan Moyal
  • Fonction : Auteur
Apolline Djelad
  • Fonction : Auteur
Charlotte Bronnimann
  • Fonction : Auteur
Lien Bekaert
  • Fonction : Auteur
Luc Taillandier
  • Fonction : Auteur
Jean-Sébastien Frenel
  • Fonction : Auteur
Olivier Langlois
  • Fonction : Auteur
Philippe Colin
  • Fonction : Auteur
Philippe Menei
  • Fonction : Auteur
Frédéric Dhermain
  • Fonction : Auteur
Catherine Carpentier
  • Fonction : Auteur
Aurélie Gerazime
  • Fonction : Auteur
Elsa Curtit
  • Fonction : Auteur
Caroline Dehais
  • Fonction : Auteur
François Ducray
  • Fonction : Auteur

Résumé

In a post hoc analysis of the CATNON trial (NCT00626990), we explored whether adding temozolomide to radiotherapy improves outcome in patients with IDH1/2 wildtype (wt) anaplastic astrocytomas with molecular features of glioblastoma [redesignated as glioblastoma, isocitrate dehydrogenase–wildtype (IDH-wt) in the 2021 World Health Organization (WHO) classification of central nervous system tumors]. Patients and Methods: From the randomized phase III CATNON study examining the addition of adjuvant and concurrent temozolomide to radiotherapy in anaplastic astrocytomas, we selected a subgroup of IDH1/2wt and H3F3Awt tumors with presence of TERT promoter mutations and/or EGFR amplifications and/or combined gain of chromosome 7 and loss of chromosome 10. Molecular abnormalities including MGMT promoter methylation status were determined by next-generation sequencing, DNA methylation profiling, and SNaPshot analysis. Results: Of the 751 patients entered in the CATNON study, 670 had fully molecularly characterized tumors. A total of 159 of these tumors met the WHO 2021 molecular criteria for glioblastoma, IDH-wt. Of these patients, 47 received radiotherapy only and 112 received a combination of radiotherapy and temozolomide. There was no added effect of temozolomide on either overall survival [HR, 1.19; 95% confidence interval (CI), 0.82–1.71] or progression-free survival (HR, 0.87; 95% CI, 0.61–1.24). MGMT promoter methylation was prognostic for overall survival, but was not predictive for outcome to temozolomide treatment either with respect to overall survival or progression-free survival. Conclusions: In this cohort of patients with glioblastoma, IDH-wt temozolomide treatment did not add benefit beyond that observed from radiotherapy, regardless of MGMT promoter status. These findings require a new well-powered prospective clinical study to explore the efficacy of temozolomide treatment in this patient population.
Fichier principal
Vignette du fichier
oyac023.pdf (3.63 Mo) Télécharger le fichier
Origine : Publication financée par une institution
licence : CC BY - Paternité

Dates et versions

hal-03976603 , version 1 (07-02-2023)

Licence

Paternité

Identifiants

Citer

Louis Garnier, Chrystelle Vidal, Olivier Chinot, Elisabeth Cohen-Jonathan Moyal, Apolline Djelad, et al.. Temozolomide and Radiotherapy versus Radiotherapy Alone in Patients with Glioblastoma, IDH -wildtype: Post Hoc Analysis of the EORTC Randomized Phase III CATNON Trial. Clinical Cancer Research, 2022, 28 (12), pp.2527-2535. ⟨10.1093/oncolo/oyac023⟩. ⟨hal-03976603⟩
25 Consultations
29 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More